SAB BIOTHERAPEUTICS, INC. Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent
SAB BIOTHERAPEUTICS, INC. (SABS) reported Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent of 3.00% for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Notes › Compensation Related Costs › Defined Contribution Plan
us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent · last filed 2026-05-12
- SAB BIOTHERAPEUTICS, INC. defined contribution plan, maximum annual contributions per employee, percent for the quarter ending 2026-03-31 was 3.00%, a 0.00% change year-over-year.
- SAB BIOTHERAPEUTICS, INC. defined contribution plan, maximum annual contributions per employee, percent for the quarter ending 2025-03-31 was 3.00%, a 0.00% change year-over-year.
- SAB BIOTHERAPEUTICS, INC. defined contribution plan, maximum annual contributions per employee, percent for the quarter ending 2024-03-31 was 3.00%, a 0.00% change year-over-year.
- SAB BIOTHERAPEUTICS, INC. defined contribution plan, maximum annual contributions per employee, percent for the quarter ending 2023-03-31 was 3.00%, a 0.00% change year-over-year.
- SAB BIOTHERAPEUTICS, INC. defined contribution plan, maximum annual contributions per employee, percent for fiscal 2025 was 3.00%, a 0.00% change from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. defined contribution plan, maximum annual contributions per employee, percent for fiscal 2024 was 3.00%, a 0.00% change from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. defined contribution plan, maximum annual contributions per employee, percent for fiscal 2023 was 3.00%, a 0.00% change from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. defined contribution plan, maximum annual contributions per employee, percent for fiscal 2022 was 3.00%, a 0.00% change from fiscal 2021.
| Period end | Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent 3 month | Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent 6 month | Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent 9 month | Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent 12 month | Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | 3.00% 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | 3.00% 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | 3.00% 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | 3.00% 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | 3.00% 10-Q · filed 2025-05-09 | ||||
| 2024-12-31 | 3.00% 10-K · filed 2025-03-31 | ||||
| 2024-09-30 | 3.00% 10-Q · filed 2024-11-06 | ||||
| 2024-06-30 | 3.00% 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | 3.00% 10-Q · filed 2024-05-20 | ||||
| 2023-12-31 | 3.00% 10-K · filed 2024-03-29 | ||||
| 2023-09-30 | 3.00% 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | 3.00% 10-Q · filed 2023-08-21 | ||||
| 2023-03-31 | 3.00% 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | 3.00% 10-K · filed 2023-04-14 | ||||
| 2022-09-30 | 2.00% 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | 2.00% 10-Q · filed 2022-08-10 | ||||
| 2022-03-31 | 3.00% 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | 3.00% 10-K/A · filed 2023-04-28 | ||||
| 2021-09-30 | 3.00% 10-Q · filed 2022-11-14 | ||||
| 2021-06-30 | 3.00% 10-Q · filed 2022-08-10 | ||||
| 2021-03-31 | 2.00% 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | 3.00% 10-K/A · filed 2023-04-28 | 2.00% 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |